ACP
RIGL icon

Acuta Capital Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

Acuta Capital Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,190
Closed -$44K – 62
2016
Q3 		$44K Buy
+1,190
New +$34.1K 0.02% 67

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Acuta Capital Partners's RIGL Position: Q3 2016 in Review

Acuta Capital Partners sold out of Rigel Pharmaceuticals (RIGL) in Q3 2016, closing a stake of 74,775 shares — an estimated $2.14M sold.

Acuta Capital Partners first reported a position in RIGL in Q3 2015 and held it in 4 quarters. The position peaked at $1.67M in Q2 2016. 121 funds tracked by Wall St. Rank hold RIGL as of Q3 2016.

  • Acuta Capital Partners reported no remaining Rigel Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 74,775 Rigel Pharmaceuticals shares in Q3 2016, an estimated $2.14M.
  • Acuta Capital Partners first reported a position in Rigel Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Acuta Capital Partners's Rigel Pharmaceuticals position peaked at $1.67M in Q2 2016.
  • 121 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2016.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.